Drug-drug interaction study between zamicastat and sildenafil in healthy subjects Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension Year: 2020
An overview of drug-drug interaction studies conducted with treprostinil Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009
The effect of fluconazole on the pharmacokinetics of ensifentrine in healthy individuals Source: Virtual Congress 2021 – Pharmacology of airway diseases: clinical and laboratory studies Year: 2021
No relevant drug-drug interaction between inhaled NVA237 and oral cimetidine Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
Pharmacokinetic characteristics of roflumilast administered in gradually increasing doses of 500μg to 1000μg are dose-linear in healthy subjects Source: Eur Respir J 2002; 20: Suppl. 38, 108s Year: 2002
Roflumilast and sildenafil in healthy male volunteers: Single-dose pharmacokinetic interactions, safety and tolerability Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Safety, pharmacokinetics, and pharmacodynamics of TD-8236, an inhaled pan-JAK inhibitor, following single- and multiple-ascending doses in healthy volunteers and mild asthmatics Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence Year: 2021
Lack of relevant pharmacokinetic and pharmacodynamic interactions between the new dual endothelin receptor antagonist macitentan and warfarin in healthy subjects Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012
A comparative study on systemic pharmacodynamic effects of two HFA formulations of salmeterol xinafoate, in healthy subjects Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010
Single-dose, first-in-human study of AMG 317: safety and pharmacokinetics in healthy and asthmatic adults Source: Annual Congress 2008 - New treatments for asthma Year: 2008
Glycopyrronium does not affect QT interval in healthy subjects: A randomized, 3-period cross-over, placebo- and positive-controlled study Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013
No significant clinical drug-drug interaction potential with indacaterol Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
Multiple-dose study of AMG 853 in healthy adults: Safety and pharmacokinetics Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
Tolerability and pharmacokinetics of inhaled bimosiamose in healthy human volunteers Source: Eur Respir J 2006; 28: Suppl. 50, 332s Year: 2006
Urinal expression profile of miRNAs after smoking cessation in healthy subjects: a pilot study Source: International Congress 2017 – Smoking and molecular findings Year: 2017
A randomised placebo controlled trial to evaluate the effects of butamirate and dextromethorphan on capsaicin induced cough in healthy volunteers Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013
Design and implementation of a multi-part, flexible protocol to assess the tolerability and pharmacodynamic effects of PUR118 in healthy subjects and COPD patients Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
Pharmacokinetics and pharmacodynamics of ciclesonide and its active principle after inhalative and intravenous administration in healthy subjects Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002
Lack of relevant pharmacokinetic interactions between the new dual endothelin receptor antagonist macitentan and sildenafil in healthy subjects Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012
Multiple-dose study of AMG 317 in adults with asthma: pharmacokinetics and safety Source: Annual Congress 2008 - New treatments for asthma Year: 2008